On August 24th, IMEiK released its semi-annual financial report. In the first half of the year, IMEiK achieved a revenue of 1.459 billion yuan ($200.5 million), a year-on-year growth of 64.93% (adjusted) and net profit of 963 million yuan ($132.32 million), a year-on-year growth of 64.66%. The basic earnings per share of 4.45 yuan ($0.61).
In terms of specific product categories, the company saw year-on-year growth in both its solution-based and gel-based injection products during the reporting period. Among them, the revenue from solution-based injection products reached 874 million yuan ($120 million), an increase of 35.90% compared to the same period last year, while the revenue from gel-based injection products reached 566 million yuan ($77.8 million), an increase of 139.00% compared to the same period last year.
IMEiK stated that the performance growth was mainly due to the gradual release of consumer demand, the gradual recovery of offline medical beauty institutions’ foot traffic, evident rebound in consumer confidence and willingness to spend, along with the company’s rich product portfolio and continuous increase in core product supply. Additionally, the strengthening of marketing system construction has driven brand value growth.
In the financial report, IMEiK also mentioned that the company has successfully achieved industrialization of skin fillers based on sodium hyaluronate, skin fillers based on polylactic acid, and polydioxanone facial embedding threads. They are also currently engaged in the development of bio-medicines such as recombinant proteins and peptides.
